Clinical Trials Logo

Chronic Liver Disease clinical trials

View clinical trials related to Chronic Liver Disease.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06432582 Recruiting - Portal Hypertension Clinical Trials

hepatomiR cACLD Study

Start date: May 15, 2024
Phase:
Study type: Observational

This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic encephalopathy) in chronic liver disease (CLD). Based on these data, it is aimed to advance the current understanding of factors driving decompensation, with potential repercussions for future risk management and therapy.

NCT ID: NCT06227988 Recruiting - Clinical trials for CHRONIC LIVER DISEASE

ASSESSMENT OF SURGICAL RISK IN PATIENTS WITH CHRONIC LIVER DISEASE USING VOCAL PENN SCORE

vocal penn 01
Start date: June 20, 2023
Phase:
Study type: Observational

4a. Primary To assess postoperative mortality at 30 and 90 days using the VOCAL PENN score 4b. Secondary To assess potential differences in prediction accuracy between VOCAL-Penn and MELD for 30 and 90-day mortality

NCT ID: NCT06160635 Recruiting - Clinical trials for Chronic Liver Disease

D-SOLVE Cohorts (Cohort A and B)

HDV750
Start date: February 22, 2023
Phase:
Study type: Observational [Patient Registry]

Hepatitis D is by far the most severe form of chronic viral hepatitis, frequently leading to liver failure, hepatocellular carcinoma and death. Hepatitis D is caused by coinfection Hepatitis D is caused by co-infection with hepatitis B virus (HBV) and hepatitis D virus (HDV). This multicenter cohort should enable a comprehensive and unbiased biomarker screening of well-defined HDV-infected patients, followed by mechanistic studies to determine the functional role of distinct molecules. Patient surveillance strategies and antiviral treatment approaches could be personalized which should reduce clinical and social disease burden, improve quality of life and save direct and indirect costs caused by HDV infection.

NCT ID: NCT05849558 Recruiting - Clinical trials for Chronic Liver Disease

Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients

URSO-003
Start date: February 22, 2022
Phase: Phase 4
Study type: Interventional

This study aims to compare the efficacy & safety of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA alone versus Placebo among Compensated Chronic Liver Diseased Patients

NCT ID: NCT05661331 Recruiting - Clinical trials for Chronic Liver Disease

VIATORR Device Registry

Start date: February 21, 2023
Phase:
Study type: Observational [Patient Registry]

The primary objective is to confirm the clinical performance and safety of the GORE® VIATORR® TIPS (Transjugular Intrahepatic Portosystemic Shunt) Endoprosthesis with Controlled Expansion throughout the device functional lifetime of 3 years in real world setting. The secondary objective is to collect information on quality of life after treatment with the GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion. Additionally, data will be collected on the safety and performance of the GORE TIPS Set when utilized.

NCT ID: NCT05653830 Recruiting - Clinical trials for Chronic Liver Disease

Observational Clinical Study of the Natural Course and Long-term Prognosis of Patients With Chronic Liver Disease

Start date: October 1, 2022
Phase:
Study type: Observational

Chronic liver disease is a global public health problem. Without timely diagnosis and treatment, chronic liver disease can progress to hepatitis, liver fibrosis, and cirrhosis, while causing a variety of complications such as gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome, and liver cancer. Early detection and treatment can slow down the progression of chronic liver disease and reduce the burden of patients. This study intends to construct a retrospective-prospective cohort of patients with chronic liver disease by building a multicenter collaborative network to study the disease characteristics, progression patterns, clinical features, natural course and long-term prognosis of chronic liver disease of different etiologies.

NCT ID: NCT05532124 Recruiting - Clinical trials for Chronic Liver Disease

Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.

NCT ID: NCT05397860 Recruiting - Clinical trials for Hepatocellular Carcinoma

Radiofrequency Ablation With Gradual Radiofrequency Energy Increment for Hepatocellular Carcinoma Treatment

Start date: January 6, 2020
Phase: N/A
Study type: Interventional

To evaluate local tumor progression rate at 12 months after percutaneous radiofrequency ablation with gradual radiofrequency energy delivery mode with Octopus electrodes in patients with hepatocellular carcinoma.

NCT ID: NCT05335603 Recruiting - Clinical trials for Chronic Liver Disease

An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis

FALL
Start date: August 24, 2020
Phase:
Study type: Observational

Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other chronic liver diseases like autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hereditary hemochromatosis and alpha-1-antitrypsin deficiency and may also develop secondary to other diseases like inflammatory bowel disease and chronic pancreatitis. Diagnosing chronic liver diseases can be challenging and treatment may be limited. In-depth phenotyping at a tissue level may generate insight into the underlying pathophysiology of diseases and furthermore identify common as well as specific diagnostic biomarkers and future treatment targets of the diseases. We therefore undertake a study that evaluates patients with chronic liver diseases associated with hepatic steatosis.

NCT ID: NCT05204251 Recruiting - Clinical trials for Chronic Liver Disease

Evaluation of the Quality of Life in Patients Referred for Transjugular Intrahepatic Portosystemic Shunt

TIPS
Start date: April 11, 2022
Phase:
Study type: Observational

Patient with Advanced Chronic Liver Disease often present portal hypertension which may lead to bleading or ascites. One of the treatment of portal hypertension in these patients is the placement of a Transjugular Intrahepatic Portosystemic Shunt (TIPS). The indications for placing TIPS take on various clinical presentations, the most classic being digestive haemorrhage by rupture of oesophageal and/or gastric varices and refractory ascites. TIPS placement involves changes in haemodynamics and liver function that may alter the patients' condition and quality of life. Very few articles have evaluated the quality of life of these patients and when quality of life is evaluated it is mostly with not adapted or not validated scales. The main objective of this study is to evaluate the quality of life of patients who have undergone TIPS using a validated and standardised quality of life questionnaire (the SF-36 questionnaire).